Impurity screening testing is a critical analytical process used to detect, identify, and quantify unwanted substances in pharmaceuticals, foods, chemicals, and consumer products, ensuring product safety and regulatory compliance. This technical guide explains impurity classification, internationally recognized thresholds under ICH and pharmacopeial standards, and the analytical techniques such as HPLC, GC-MS, LC-MS/MS, and ICP-MS used by accredited third-party laboratories. Understanding impurity screening helps manufacturers control quality risks, meet global regulatory expectations, and accelerate product development.
Technical Overview
Impurity screening testing refers to the systematic analytical evaluation of a substance or product to discover, identify, and quantify chemical entities that are not the intended active or principal component. Impurities may arise from raw materials, synthesis pathways, degradation reactions, manufacturing equipment, excipients, or packaging contact materials. Because many impurities are potentially toxic, genotoxic, or capable of affecting product stability and efficacy, regulatory authorities worldwide have established strict limits and reporting requirements for them.
In the pharmaceutical field, impurities are conventionally classified into three categories according to ICH Q3A(R2) and Q3B(R2): organic impurities (starting materials, by-products, intermediates, reagents, and degradation products), inorganic impurities (reagents, ligands, heavy metals, inorganic salts, and catalysts), and residual solvents governed by ICH Q3C(R8). Elemental impurities are controlled separately under ICH Q3D(R2), while mutagenic and genotoxic impurities are assessed under ICH M7(R2) using the Threshold of Toxicological Concern (TTC) concept, generally 1.5 µg per day for lifetime exposure. Comparable frameworks exist for food safety (GB, ISO, and EN standards), cosmetics, and industrial chemicals.
A complete impurity screening program typically combines broad-spectrum detection, structural identification of unknown peaks, accurate quantification against reference standards, and toxicological risk assessment. The resulting impurity profile becomes the foundation for specification setting, stability studies, and regulatory submissions.
Testing Samples
Active Pharmaceutical Ingredients (APIs) and Intermediates
Drug substances and their synthetic intermediates are screened for process-related impurities such as unreacted starting materials, by-products, residual catalysts, and reagents. Early-stage screening of synthetic routes helps manufacturers select the cleanest process and define control points.
Drug Products and Finished Dosage Forms
Tablets, capsules, injectables, oral solutions, and topical formulations are tested for degradation products formed during manufacturing, storage, or interaction between API and excipients. Screening supports shelf-life determination and storage condition selection.
Excipients and Packaging Materials
Excipients, elastomer closures, plastic containers, and delivery devices are evaluated for extractables and leachables (E&L), following frameworks such as USP <1663> and USP <1664>, PQRI guidance, and ISO 10993 for medical devices.
Foods, Cosmetics, and Consumer Products
Food additives, dietary supplements, cosmetics, and household chemical products are screened for contaminants including heavy metals, pesticide residues, mycotoxins, nitrosamines, and illegal colorants, in accordance with GB, ISO, EN, and JIS requirements.
Fine Chemicals and Polymers
Specialty chemicals, monomers, catalysts, and polymer materials are characterized for residual monomers, oligomers, metal residues, and volatile organic impurities that may affect downstream applications or regulatory status.
Testing Items
Typical impurity screening testing items include:
- Organic impurities and related substances, including process impurities and degradation products
- Residual solvents, classified as Class 1, 2, or 3 per ICH Q3C
- Elemental impurities and heavy metals, including Pb, As, Cd, Hg, Co, V, Ni, and other Class 1–3 elements per ICH Q3D
- Genotoxic and mutagenic impurities, including nitrosamines, alkyl halides, and azo compounds
- Residual starting materials, catalysts, ligands, and reagents
- Extractables and leachables from packaging and delivery systems
- Chiral and enantiomeric impurities for optically active compounds
- Inorganic ions, counterions, and salts
- Oligomers and polymer-related impurities in macromolecular products
- Water content and volatile contaminants
Testing Methods
Impurity screening relies on a combination of chromatographic, spectrometric, and elemental techniques, selected according to the physicochemical nature of the analyte and the required sensitivity:
- HPLC with UV/DAD detection: the workhorse method for related substances profiling, offering robust separation and quantification of non-volatile organic impurities
- UHPLC and two-dimensional LC: enhanced resolution for complex impurity profiles and co-eluting peaks
- LC-MS/MS and high-resolution LC-MS (QTOF/Orbitrap): identification of unknown impurities through accurate mass measurement and fragmentation data, with sensitivity down to ppm or ppb levels required for genotoxic impurity control
- GC-MS and headspace GC: determination of residual solvents and volatile organic impurities, consistent with USP <467> and ICH Q3C
- ICP-MS and ICP-OES: trace-level quantification of elemental impurities in line with USP <232>/<233> and ICH Q3D
- NMR spectroscopy: definitive structural elucidation of unknown impurities isolated at preparative scale
- Ion chromatography: determination of inorganic anions, cations, and counterions
- Chiral HPLC and SFC: separation and quantification of enantiomeric impurities
- SEC/GPC: characterization of oligomeric impurities in polymers and biologics
All quantitative methods are validated for specificity, accuracy, precision, linearity, range, quantification limit, and robustness in accordance with ICH Q2(R2). Where an impurity reference standard is unavailable, quantification may be performed using a relative response factor approach, with subsequent standardization once the impurity is identified and synthesized. Forced degradation studies under hydrolytic, oxidative, thermal, and photolytic conditions are often integrated into screening programs to reveal potential degradation pathways.
Applications
Impurity screening testing supports a wide range of industrial and regulatory objectives:
- Pharmaceutical development: impurity profiling during API synthesis optimization, formulation development, and method development for regulatory submissions
- Stability programs: monitoring impurity growth under ICH Q1A(R2) long-term and accelerated storage conditions
- Generic drug development: demonstrating equivalence of impurity profiles to reference listed products
- Manufacturing troubleshooting: root-cause investigation of out-of-specification results, batch failures, and process deviations
- Packaging qualification: extractables and leachables studies for container closure systems and drug-device combinations
- Food and cosmetic safety: verification of contaminant limits for heavy metals, pesticide residues, and prohibited substances
- Supply chain control: incoming material verification and vendor qualification
- Regulatory compliance: support for CMC documentation, pharmacopeial monograph conformity (USP, EP, JP, ChP), and post-approval change management
FAQ
What is the difference between impurity screening and impurity profiling?
Impurity screening is a broad-spectrum, discovery-oriented analysis designed to detect as many impurities as possible, including unknown peaks. Impurity profiling goes further, involving structural identification, quantification, and toxicological evaluation of each detected impurity to establish a complete impurity profile for control purposes.
What are identification and qualification thresholds?
Per ICH Q3A(R2) and Q3B(R2), the reporting threshold defines the level at which an impurity must be reported in a certificate of analysis, the identification threshold defines the level at which its structure must be elucidated, and the qualification threshold defines the level at which it must be evaluated for biological safety. These thresholds are expressed as percentages and vary with the maximum daily dose of the drug substance.
How are unknown impurities identified?
Unknown impurities are typically isolated or enriched by preparative chromatography, then characterized using high-resolution mass spectrometry, tandem MS fragmentation, and NMR spectroscopy. Accurate mass data, isotope patterns, and proposed fragmentation pathways allow structural hypotheses that are confirmed against synthesized reference material.
What are extractables and leachables?
Extractables are compounds that can be drawn out of a packaging material or device under aggressive laboratory conditions such as solvents, elevated temperature, or extended contact time. Leachables are the subset that actually migrates into the product under normal storage and use conditions. Both are controlled through risk-based screening programs aligned with USP <1663>/<1664> and related guidance.
How sensitive is impurity screening testing?
Modern LC-MS/MS and GC-MS platforms routinely achieve limits of quantification in the ppm to ppb range, which is essential for controlling genotoxic impurities against the 1.5 µg/day TTC limit. ICP-MS achieves sub-ppb detection for most elemental impurities, comfortably supporting ICH Q3D permitted exposure limits.
Why should impurity screening be outsourced to accredited third-party laboratories?
Accredited laboratories possess validated instrumentation, comprehensive impurity reference libraries, experienced structural elucidation scientists, and quality systems aligned with ISO/IEC 17025. Partnering with such laboratories provides scientifically defensible data for regulatory submissions, dispute resolution, and independent verification of in-house results.